LIVN Stock Recent News

LONDON--(BUSINESS WIRE)-- #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York. The presentation will take place Thurs., June 5, at 3:10 p.m. Eastern Time. The discussion will be available to all interested parties who register to attend the webcast, which is accessible via www.livanova.com/events. Listeners should log on.

LivaNova PLC (NASDAQ:LIVN ) Q1 2025 Earnings Conference Call May 7, 2025 8:00 AM ET Company Participants Briana Gotlin – Vice President, Investor Relations Vladimir Makatsaria – Chief Executive Officer Ahmet Tezel – Chief Innovation Officer Alex Shvartsburg – Chief Financial Officer Stephanie Bolton – President, Global Epilepsy Conference Call Participants Rick Wise – Stifel David Roman – Goldman Sachs Adam Maeder – Piper Sandler Mike Sarcone – Jefferies Mike Matson – Needham & Co. David Rescott – Baird Michael Polark – Wolfe Research Operator Good day, ladies and gentlemen, and welcome to the LivaNova PLC First Quarter 2025 Earnings Conference Call. My name is Emily, and I'll be coordinating your call today.

LivaNova (LIVN) came out with quarterly earnings of $0.88 per share, beating the Zacks Consensus Estimate of $0.75 per share. This compares to earnings of $0.73 per share a year ago.

LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the first quarter ended March 31, 2025 and updated full-year 2025 guidance. Financial Summary and Highlights(1) First-quarter revenue of $316.9 million increased 7.4% on a reported basis, 8.9% on a constant-currency basis, and 10.4% on an organic basis as compared to the prior-year period First-quarter U.S. GAAP diluted loss per share of $6.01, impacted by recording SNIA.

LONDON--(BUSINESS WIRE)-- #livn--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced 12-month, top-line data from its OSPREY randomized controlled trial (RCT), evaluating outcomes with the aura6000™ System for the treatment of moderate to severe obstructive sleep apnea (OSA). At 12 months of therapy, the treatment arm responder rate was 65% with responders defined as those who realized at least a 50% improvement from the baseline apnea-hypopnea index (AHI) and an A.

LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC will host a conference call to discuss its first-quarter 2025 results on Wed., May 7, 2025, at 1 p.m. London time (8 a.m. Eastern Time).

LivaNova (LIVN) came out with quarterly earnings of $0.81 per share, beating the Zacks Consensus Estimate of $0.80 per share. This compares to earnings of $0.87 per share a year ago.

LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC today reported fourth-quarter and full-year 2024 results and issued full-year 2025 guidance.

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Barclays Global Healthcare Conference in Miami, Florida. The presentation will take place at 2:00 p.m. Eastern Time on Tuesday, March 11. The discussion will be available to all interested parties who register to attend the webcast, which is accessible via www.livanova.com/events. Listeners should.

LONDON--(BUSINESS WIRE)-- #LIVN--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2024 results on Tuesday, February 25, 2025 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its fourth-quarter and full-year 2024 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to rec.